Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2015
The CRH1 antagonist GSK561679 increases human fear but not anxiety as assessed by startle.
Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 47 citations in OpenAlex.
- Trial
- Neurophysiological and clinical effects of the NMDA receptor antagonist lanicemine (BHV-5500) in PTSD: A randomized, double-blind, placebo-controlled trial.Depression and anxiety · 2021Trial
- The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.Psychopharmacology · 2021Trial
- Psychophysiological treatment outcomes: Corticotropin-releasing factor type 1 receptor antagonist increases inhibition of fear-potentiated startle in PTSD patients.Psychophysiology · 2020Trial
- Acute prazosin administration does not reduce stressor reactivity in healthy adults.Psychopharmacology · 2019Trial
- Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder.Biological psychiatry · 2017Trial
- The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2016Trial
- Neuropeptidergic systems in psychiatric disorders.Frontiers in endocrinology · 2025Review
- Beyond Fear, Extinction, and Freezing: Strategies for Improving the Translational Value of Animal Conditioning Research.Current topics in behavioral neurosciences · 2023Article
- Corticotropin releasing factor (CRF) systems: Promoting cocaine pursuit without distress via incentive motivation.PloS one · 2022Article
- Cross-species anxiety tests in psychiatry: pitfalls and promises.Molecular psychiatry · 2022Review
- Activating Corticotropin-Releasing Factor Systems in the Nucleus Accumbens, Amygdala, and Bed Nucleus of Stria Terminalis: Incentive Motivation or Aversive Motivation?Biological psychiatry · 2021Article
- A way forward for anxiolytic drug development: Testing candidate anxiolytics with anxiety-potentiated startle in healthy humans.Neuroscience and biobehavioral reviews · 2020Review
- Paeoniflorin regulates the hypothalamic-pituitary-adrenal axis negative feedback in a rat model of post-traumatic stress disorder.Iranian journal of basic medical sciences · 2020Article
- Modeling anxiety in healthy humans: a key intermediate bridge between basic and clinical sciences.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2019Review
- Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future.Neuroscience and biobehavioral reviews · 2019Review
- Exercise modulates the interaction between cognition and anxiety in humans.Cognition & emotion · 2019Article
- Oxytocin facilitates adaptive fear and attenuates anxiety responses in animal models and human studies-potential interaction with the corticotropin-releasing factor (CRF) system in the bed nucleus of the stria terminalis (BNST).Cell and tissue research · 2019Review
- Anti-stress neuropharmacological mechanisms and targets for addiction treatment: A translational framework.Neurobiology of stress · 2018Review
- Exercise decreases defensive responses to unpredictable, but not predictable, threat.Depression and anxiety · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Fear to predictable threat and anxiety to unpredictable threat reflect distinct processes mediated by different brain structures, the central nucleus of the amygdala and the bed nucleus of the stria terminalis (BNST), respectively. This study tested the hypothesis that the corticotropin-releasing factor (CRF1) antagonist GSK561679 differentially reduces anxiety but increases fear in humans. A total of 31 healthy females received each of four treatments: placebo, 50 mg GSK561679 (low-GSK), 400 mg GSK561679 (high-GSK), and 1 mg alprazolam in a crossover design. Participants were exposed to three conditions during each of the four treatments. The three conditions included one in which predictable aversive shocks were signaled by a cue, a second during which shocks were administered unpredictably, and a third condition without shock. Fear and anxiety were assessed using the acoustic startle reflex. High-GSK had no effect on startle potentiation during unpredictable threat (anxiety) but increased startle potentiation during the predictable condition (fear). Low-GSK did not affect startle potentiation across conditions. Consistent with previous findings, alprazolam reduced startle potentiation during unpredictable threat but not during predictable threat. The increased fear by high-GSK replicates animal findings and suggests a lift of the inhibitory effect of the BNST on the amygdala by the CRF1 antagonist.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.